Cargando…
Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study()
OBJECTIVE: Frontotemporal dementia (FTD) is characterized by behavioral disturbances and language problems. Familial forms can be caused by genetic defects in microtubule-associated protein tau (MAPT), progranulin (GRN), and C9orf72. In light of upcoming clinical trials with potential disease-modify...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011170/ https://www.ncbi.nlm.nih.gov/pubmed/27625986 http://dx.doi.org/10.1016/j.nicl.2016.08.001 |
_version_ | 1782451776147947520 |
---|---|
author | Dopper, Elise G.P. Chalos, Vicky Ghariq, Eidrees den Heijer, Tom Hafkemeijer, Anne Jiskoot, Lize C. de Koning, Inge Seelaar, Harro van Minkelen, Rick van Osch, Matthias J.P. Rombouts, Serge A.R.B. van Swieten, John C. |
author_facet | Dopper, Elise G.P. Chalos, Vicky Ghariq, Eidrees den Heijer, Tom Hafkemeijer, Anne Jiskoot, Lize C. de Koning, Inge Seelaar, Harro van Minkelen, Rick van Osch, Matthias J.P. Rombouts, Serge A.R.B. van Swieten, John C. |
author_sort | Dopper, Elise G.P. |
collection | PubMed |
description | OBJECTIVE: Frontotemporal dementia (FTD) is characterized by behavioral disturbances and language problems. Familial forms can be caused by genetic defects in microtubule-associated protein tau (MAPT), progranulin (GRN), and C9orf72. In light of upcoming clinical trials with potential disease-modifying agents, the development of sensitive biomarkers to evaluate such agents in the earliest stage of FTD is crucial. In the current longitudinal study we used arterial spin labeling MRI (ASL) in presymptomatic carriers of MAPT and GRN mutations to investigate early changes in cerebral blood flow (CBF). METHODS: Healthy first-degree relatives of patients with a MAPT or GRN mutation underwent ASL at baseline and follow-up after two years. We investigated cross-sectional and longitudinal differences in CBF between mutation carriers (n = 34) and controls without a mutation (n = 31). RESULTS: GRN mutation carriers showed significant frontoparietal hypoperfusion compared with controls at follow-up, whereas we found no cross-sectional group differences in the total study group or the MAPT subgroup. Longitudinal analyses revealed a significantly stronger decrease in CBF in frontal, temporal, parietal, and subcortical areas in the total group of mutation carriers and the GRN subgroup, with the strongest decrease in two mutation carriers who converted to clinical FTD during follow-up. INTERPRETATION: We demonstrated longitudinal alterations in CBF in presymptomatic FTD independent of grey matter atrophy, with the strongest decrease in individuals that developed symptoms during follow-up. Therefore, ASL could have the potential to serve as a sensitive biomarker of disease progression in the presymptomatic stage of FTD in future clinical trials. |
format | Online Article Text |
id | pubmed-5011170 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-50111702016-09-13 Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() Dopper, Elise G.P. Chalos, Vicky Ghariq, Eidrees den Heijer, Tom Hafkemeijer, Anne Jiskoot, Lize C. de Koning, Inge Seelaar, Harro van Minkelen, Rick van Osch, Matthias J.P. Rombouts, Serge A.R.B. van Swieten, John C. Neuroimage Clin Regular Article OBJECTIVE: Frontotemporal dementia (FTD) is characterized by behavioral disturbances and language problems. Familial forms can be caused by genetic defects in microtubule-associated protein tau (MAPT), progranulin (GRN), and C9orf72. In light of upcoming clinical trials with potential disease-modifying agents, the development of sensitive biomarkers to evaluate such agents in the earliest stage of FTD is crucial. In the current longitudinal study we used arterial spin labeling MRI (ASL) in presymptomatic carriers of MAPT and GRN mutations to investigate early changes in cerebral blood flow (CBF). METHODS: Healthy first-degree relatives of patients with a MAPT or GRN mutation underwent ASL at baseline and follow-up after two years. We investigated cross-sectional and longitudinal differences in CBF between mutation carriers (n = 34) and controls without a mutation (n = 31). RESULTS: GRN mutation carriers showed significant frontoparietal hypoperfusion compared with controls at follow-up, whereas we found no cross-sectional group differences in the total study group or the MAPT subgroup. Longitudinal analyses revealed a significantly stronger decrease in CBF in frontal, temporal, parietal, and subcortical areas in the total group of mutation carriers and the GRN subgroup, with the strongest decrease in two mutation carriers who converted to clinical FTD during follow-up. INTERPRETATION: We demonstrated longitudinal alterations in CBF in presymptomatic FTD independent of grey matter atrophy, with the strongest decrease in individuals that developed symptoms during follow-up. Therefore, ASL could have the potential to serve as a sensitive biomarker of disease progression in the presymptomatic stage of FTD in future clinical trials. Elsevier 2016-08-03 /pmc/articles/PMC5011170/ /pubmed/27625986 http://dx.doi.org/10.1016/j.nicl.2016.08.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Dopper, Elise G.P. Chalos, Vicky Ghariq, Eidrees den Heijer, Tom Hafkemeijer, Anne Jiskoot, Lize C. de Koning, Inge Seelaar, Harro van Minkelen, Rick van Osch, Matthias J.P. Rombouts, Serge A.R.B. van Swieten, John C. Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title | Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title_full | Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title_fullStr | Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title_full_unstemmed | Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title_short | Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study() |
title_sort | cerebral blood flow in presymptomatic mapt and grn mutation carriers: a longitudinal arterial spin labeling study() |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5011170/ https://www.ncbi.nlm.nih.gov/pubmed/27625986 http://dx.doi.org/10.1016/j.nicl.2016.08.001 |
work_keys_str_mv | AT dopperelisegp cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT chalosvicky cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT ghariqeidrees cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT denheijertom cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT hafkemeijeranne cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT jiskootlizec cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT dekoninginge cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT seelaarharro cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT vanminkelenrick cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT vanoschmatthiasjp cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT romboutssergearb cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy AT vanswietenjohnc cerebralbloodflowinpresymptomaticmaptandgrnmutationcarriersalongitudinalarterialspinlabelingstudy |